ICLs effective over long-periods

Article

The use of implantable collamer lenses (ICLs) to correct moderate to high myopia can offer predictable and stable results over a long period of time, according to a report published in the July issue of Archives of Ophthalmology.

The use of implantable collamer lenses (ICLs) to correct moderate to high myopia can offer predictable and stable results over a long period of time, according to a report published in the July issue of Archives of Ophthalmology.

Kazutaka Kamiya, MD, PhD and colleagues from the University of Kitasato School of Medicine and Sanno Hospital, Tokyo, Japan conducted a study to determine the long-term clinical outcomes of implantation of a biocompatible collagen copolymer lens (Visian ICL, STAAR Surgical) in patients with high to moderate myopia. A total of 56 eyes (34 patients) with myopic refractive errors of -4 to -15.25 D received the lens and follow-up examinations were conducted 1, 3 and 6 months and 1, 2 and 4 years following surgery.

At four years postoperative, 79% of eyes were within ±0.5 D of target refraction and 93% were within ±1 D of target refraction. Mean manifest changes in refraction of -0.24 D occurred from 1 month to 4 years and no vision-threatening complications were observed.

The results of this study suggest that ICLs are safe and effective and can offer stable refractive results even over long time periods making them a suitable treatment option for eyes with moderate to high myopia.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.